To assess the sensitivity to cisplatin of human glioblastoma, we treated in vitro two representative long-term cultures with different doses of cisplatin (CDDP) and assayed K-Ras4B protein abundance by semiquantitative Western Blot. The gene discussed is KRAS; the disease is glioblastoma.